@misc{Bartuś_Krzysztof_The_2010,
 author={Bartuś, Krzysztof},
 address={Kraków},
 howpublished={online},
 year={2010},
 school={Wydział Lekarski},
 language={pol},
 abstract={Aim: The use of the 3 F Therapeutics (ATS Medical) Stentless Equine Pericardial Bio-prosthesis in prospective evaluation. Methods: Study population consists of 45 patients- 1O female and 35 male, qualified for aortic valve replacement surgery, in 1 year observation. Results: Post-operative NYHA improvement was observed in all the study subjects. No complications were reported for 41 patients. Two patients experienced an episode of bleeding, 2 died not releted to the valve. No reports of valve dysfunction, paravalvular leak, endocarditis, stroke, hemolisis, or thromboembolic events. Mean gradient was 8.6 mmHg at discharge; 7.8 mmHg at 3-6 months, and 7. 7 mmHg at 1 year follow-up. The maximum gradient was 16.1 mmHg at discharge; 14.5 mmHg at 3-6 months; and 14.4 mmHg at 1 year. An average EOA was 2.6 cm2 at discharge and did not show statistically significant changes. One patient had small AI post operatively. At 3-6 months: 12 patients had minor AI, 8- small, 2-moderate. At 1 year follow-up AI was hemodinamically insignificant in 3 7 patients; moderate in 3; and large in 1 patient. Conclusion: General patients condition improved based on NYHA. No complications related to the study valve were observed and no reoperation was needed. The study showed better hemodynamic performance of the 3F valve compare to the results published.},
 title={The use of stentless equine pericardial valve in treatment of aquired aortic valve disease},
 type={Praca doktorska},
 keywords={stentless valve, biological valves, bioprothesis},
}